We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+8.55%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$481M
AUM Growth
-$55.4M
Cap. Flow
-$94.9M
Cap. Flow %
-19.73%
Top 10 Hldgs %
37.24%
Holding
92
New
28
Increased
9
Reduced
23
Closed
26

Top Buys

1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13.5M
2
NVRO
NEVRO CORP.
NVRO
+$13.2M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$11.6M
4
ENDP
Endo International plc
ENDP
+$8.8M
5
INSM icon
Insmed
INSM
+$8.11M

Top Sells

1
CLVS
Clovis Oncology, Inc.
CLVS
+$12.2M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.84M
3
MRK icon
Merck
MRK
+$9.57M
4
ELGX
Endologix Inc
ELGX
+$9.41M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$9.22M

Sector Composition

1 Healthcare 58.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
26
DELISTED
TESARO, Inc.
TSRO
$6.99M 1.45%
+50,000
New +$7.24M
NBIX icon
27
Neurocrine Biosciences
NBIX
$17.2B
$6.9M 1.43%
150,000
-150,000
-50% -$7.28M
NXTM
28
DELISTED
NxStage Medical Inc.
NXTM
$6.52M 1.35%
260,000
+60,000
+30% +$1.49M
FXB icon
29
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.6M
$6.46M 1.34%
+50,900
New +$6.35M
IRTC icon
30
iRhythm Holdings
IRTC
$3.64B
$6.37M 1.32%
+150,000
New +$5.46M
ITCI
31
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.21M 1.29%
+500,000
New +$5.8M
ENTL
32
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$6.21M 1.29%
375,000
– –
NVDQ
33
DELISTED
Novadaq Technologies Inc.
NVDQ
$5.86M 1.22%
500,000
-400,000
-44% -$3.16M
NSTG
34
DELISTED
NanoString Technologies, Inc.
NSTG
$5.79M 1.2%
350,000
-50,000
-13% -$883K
ALXN
35
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$5.47M 1.14%
+45,000
New +$5.24M
GILD icon
36
Gilead Sciences
GILD
$167B
$5.31M 1.1%
+75,000
New +$4.99M
KITE
37
CALL
DELISTED
Kite Pharma, Inc.
KITE
$5.18M 1.08%
+50,000
New +$4.08M
AIMT
38
DELISTED
Aimmune Therapeutics
AIMT
$5.14M 1.07%
+250,000
New +$4.77M
ATRA icon
39
Atara Biotherapeutics
ATRA
$75.6M
$4.9M 1.02%
+14,000
New +$5.39M
VRAY
40
DELISTED
ViewRay, Inc.
VRAY
$4.85M 1.01%
+750,000
New +$5.02M
BSX icon
41
Boston Scientific
BSX
$65.4B
$4.85M 1.01%
175,000
-275,000
-61% -$7.3M
NGNE icon
42
Neurogene
NGNE
$744M
$4.22M 0.88%
15,000
+3,750
+33% +$1.07M
ARGX icon
43
argenx
ARGX
$53.8B
$4.16M 0.87%
+196,287
New +$4.09M
SIOX
44
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$4.06M 0.84%
+21,875
New +$3.83M
IOVA icon
45
Iovance Biotherapeutics
IOVA
$2.23B
$4.04M 0.84%
550,000
-650,000
-54% -$4.13M
SAGE
46
DELISTED
Sage Therapeutics
SAGE
$3.98M 0.83%
50,000
-50,000
-50% -$3.61M
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.36B
$3.75M 0.78%
675,000
-825,000
-55% -$5.03M
CBAY
48
DELISTED
Cymabay Therapeutics
CBAY
$3.74M 0.78%
650,000
+150,000
+30% +$639K
PTCT icon
49
PTC Therapeutics
PTCT
$6.52B
$3.67M 0.76%
200,000
– –
KTWO
50
DELISTED
K2M Group Holdings, Inc
KTWO
$3.65M 0.76%
150,000
-135,000
-47% -$3M
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Ghost Tree Capital held 92 positions worth $481M, down 10% from $537M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ghost Tree Capital withdrew a net $94.9M in Q2 2017, closing 26 positions and reducing 23 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $12.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 60% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $12.5M.

  • Ghost Tree Capital's largest Q2 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 125,000 shares worth $12.5M.
  • Ghost Tree Capital added most to Seagen Inc. Common Stock in Q2 2017, an estimated $6.36M increase.
  • Ghost Tree Capital's biggest Q2 2017 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $9.22M.
  • Ghost Tree Capital fully exited Clovis Oncology, Inc. in Q2 2017, selling an estimated $12.2M.
  • Ghost Tree Capital's ten largest holdings make up 37% of its $481M portfolio in Q2 2017.
  • Ghost Tree Capital opened 28 new positions and closed 26 in Q2 2017.
  • Ghost Tree Capital's portfolio value fell 10% quarter-over-quarter to $481M.

Based on Ghost Tree Capital's 13F filing for Q2 2017, filed 14 Aug 2017.